在当代基于社区的患有转移性清细胞细胞癌的患者中改善了生存率,这些患者正在接受积极治疗
Reha-Baris Incesu1,2, Simone Morra1,3, Lukas Scheipner1,4
1Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
概括
与历史组相比,患有清细胞转移性细胞癌 (ccmRCC) 的当代患者的整体存活率 (OS) 显著改善. 这些发现表明,在社区环境中有效地应用先进的治疗方法.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 流行病学 流行病学
背景情况:
- 从III期试验中演变的治疗模式可能会改善转移性细胞癌的结果.
- 研究当代治疗对清细胞转移性细胞癌 (ccmRCC) 整体存活率的影响至关重要.
研究的目的:
- 评估现代治疗策略是否改善了当代社区患者ccmRCC的整体存活率.
- 为了比较接受积极治疗的ccmRCC患者当代和历史队列之间的生存结果.
主要方法:
- 对2017-2020年 (当代) 和2010-2016年 (历史) ccmRCC患者的SEER数据库分析.
- 患者根据治疗方式进行分类:全身疗法 (ST),细胞还原性腎切除术 (CN) 或两者 (ST+CN).
- 用单变量和多变量Cox回归模型来评估生存差异.
主要成果:
- 当代患者 (32%) 的平均寿命为41个月,而历史患者 (68%) 的平均寿命为25个月 (P<.001).
- 当代会员独立地与较低的整体死亡率相关 (HR,0.7;P<.001).
- 与历史相比,当代组的所有治疗小组 (仅ST,仅CN,ST+CN) 均观察到改善的生存状况.
结论:
- 与历史同行相比,接受积极治疗的当代社区ccmRCC患者的生存率更高.
- 第三阶段试验的进展似乎在非专业化癌症中心得到了有效实施.
更多相关视频
相关概念视频
01:21Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K